Kornimate/medical-research-clean huggingface dataset:
brain imaging in early psychosis

Conditions: Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse)

Summary: this study assesses brain connectivity and function of individuals ages 13-25 at a prodromal or early stage of a psychotic disorder. participation involves approximately 3 hours of mri scanning and up to 6 hours of behavioral testing at washington university school of medicine's campus.

schizophrenia is a devastating illness inflicting about 1% of the population worldwide. symptoms of schizophrenia include paranoia, hallucinations, and disorganized behaviors, and is associated with lifelong occupational and social disability. it typically develops in adolescence or early adulthood, which are particularly formative periods in life when major educational, vocational, and social life changes occur, and then the brain undergoes a rearrangement of critical neural circuits. the "prodrome" is the period before the onset of a psychotic disorder, like schizophrenia. prodromal youth often have significant emotional distress and social withdrawal, and family members may observe a concerning change in behavior or school or work performance. identifying those at clinical high risk for a psychotic disorder is important, as early intervention can improve symptoms and functioning, and could prevent the eventual development of a psychotic disorder. this study will focus on individuals aged 13-25 years who have met criteria for a psychosis-risk syndrome (or attenuated psychosis syndrome) or are at a very early stage (first 3 years after diagnosis) of a psychotic disorder, such as schizophrenia or schizoaffective disorder. involvement will be either 2 or 3 partial days at washington university and will involve approximately 3 hours of mri scanning and up to 6 hours of behavioral testing. additionally, the investigators will study the effect of genetics on the patterns of brain connectivity in various psychiatric populations. dna will be collected non-invasively from saliva and stored and processed in washington university facilities.

Eligibility criteria:
inclusion criteria: * male or female between the ages of 13 and 25 * meet diagnostic criteria for a prodromal syndrome or early psychosis by either meeting: 1) criteria for psychosis-risk on the structured assessment of psychosis-risk syndrome, or 2) meeting criteria for a psychotic disorder on the scid diagnostic interview only within the last 3 years. * understand and sign an informed consent (or assent form for minors) document in english exclusion criteria: * iq of 70 or under * past or current history of clinically significant central nervous system disorder that may contribute to psychotic symptoms or confound their assessment * pregnancy * the diagnostic symptoms are clearly caused by an axis i disorder, including substance use disorders, as judged by the evaluating clinician.

Keywords: early psychosis prodrome schizophrenia psychosis
effectiveness of 'nexpowder' for hemostatic treatments of nonvariceal, upper gastrointestinal bleeding

Conditions: Nonvariceal Upper Gastrointestinal Bleeding

Summary: a prospective, multi-center, randomized controlled trial to evaluate safety and effectiveness of endoscopic hemostatic powder, 'nexpowder' for hemostatic treatments of nonvariceal upper gastrointestinal bleeding. this study is a prospective, multi-center, single blind (for patients), controlled investigation planned to evaluate safety and effectiveness of nexpowder with 352 subject patients.

this investigational study is designed to compare effectiveness of using the standard-of-care hemostatic therapy only, versus the standard-of-care hemostatic therapy plus an additional hemostatic treatment using nexpower for patients with nonvariceal, upper gastrointestinal bleeding from ulcers with high-risk stigmata (forrest classification ia, ib, or iia). the primary end-points will be evaluated by assessing the rates of re-bleeding, which occur over three (3) days following initial hemostasis achieved with the standard-of-care hemostatic therapy. secondary end-points consist of evaluating three items: 1) ease of use of nexpowder applied for the test group after reaching initial hemostasis, 2) nexpowder device malfunction and 3) safety follow-up to check occurrence of adverse event(s)/re-bleeding at 30-day (+5) time point. only the subjects whose initial hemostasis has been achieved will be registered for this investigation but those who initial hemostasis has failed to be reached with the standard-of-care therapie(s) shall not be registered for this investigation.

Eligibility criteria:
inclusion criteria: * adult male or female with age of older than 19 years. * patients showing non-variceal upper gi bleeding symptoms * an endoscopic examination indicates that the patients's ulcer is categorized class ia, ib, or iia according to the forrest classifications. exclusion criteria: * pregnant or breast-feeding patients
dmbss-a randomized trial of different laparoscopic gastric bypass surgery in patients with obesity-related t2dm

Conditions: Diabetes Mellitus Type 2 in Obese

Summary: the investigators would like to conduct a randomized clinical trial to compare the efficacy of diabetes treatment between different gastric bypass procedures involving type 2 diabetics patients with bmi from 27.5 to 35 kg/m2

the investigators would like to conduct a randomized clinical trial to compare the efficacy of diabetes treatment between different gastric bypass procedures involving type 2 diabetics patients with bmi from 27.5 to 35 kg/m2. this program will determine the relative effectiveness among lmgb 、rygb and sadjb .the primary end point including hba1c\<6.0%, ldl-c\<100mg/dl and sbp\<130mmhg at one year after surgery. through this study, the investigators may understand which gastric bypass is the best for type 2 diabetic's treatment. the investigators also hope some new treatment modulation may be developed.

Eligibility criteria:
inclusion criteria: * age 20 to 67 years * diagnosed with t2dm at least 6 months prior to enrollment, under the active care of a doctor for at least the six months prior to enrollment, hba1c ≥ 7.5 % * body mass index (bmi) ≥ 27.5 kg/m 2 and ≤ 34.9 kg/m 2 * willingness to accept random assignment to either treatment group. * willingness to comply with the follow-up protocol * written informed consent. exclusion criteria: * cardiovascular event (myocardial infarction, acute coronary syndrome, coronary artery angioplasty or bypass, stroke) in the past six months. * current evidence of congestive heart failure, angina pectoris, or symptomatic peripheral vascular disease. * cardiac stress test indicating that surgery would not be safe. * pulmonary embolus or thrombophlebitis in the past six months * cancer of any kind (except basal cell skin cancer or cancer in situ) unless documented to be disease-free for five years * serum creatinine ≥ 1.5 mg/dl * history of stomach surgery, bile duct surgery, pancreatic surgery, splenectomy, or colon resection * previous organ transplantation. * history of alcohol or drug dependency * current participation in a conflicting research protocol.

Keywords: type 2 diabetes mellitus (t2dm) obesity laparoscopic gastric bypass duodenum exclusion
short-term effect of pomegranate juice on blood sugar and its controlling hormones in pre-diabetic and type ii diabetic patients.

Conditions: Patients With Type 2 Diabetes (FSG: More Than 7.1 and Not Higher Than 15.8 mmol/L)

Summary: fresh pomegranate juice at 1.5 ml/kg of body weight was administered by recruited healthy individuals and patients with type 2 diabetes of fasting serum glucose between 7.1 and 15.8 mmol/l after approximately 12 hours fasting. blood samples were collected in plain tubes before (-5 minutes) and at 1 and 3 hours after drinking pomegranate juice. blood samples were centrifuged and serum was collected and stored for glucose and hormonal analysis. patients were recruited from those of earlier stages of type 2 diabetes, and many of them already drink pomegranate juice as of its benefits for their health). the exclusion criteria included subjects with renal or hepatic disease, pregnancy, treatment with insulin, and hormone therapies. participants who had either smoked cigarettes or taken antioxidant supplements, lipid-lowering drugs, and oral hypoglycemic agents, such as metformin (glucophage) or sulfonylureas, within the preceding 12 hours were also excluded. the study was explained to all of the recruited subjects by the clinical researchers, and written informed consent was obtained prior to enrollment. approval for the study was provided by the irb committee at jordan university of science and technology (irbid, jordan).


Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes at early stages of progression (fasting serum glucose: 7.1 - 15.8 mmol/l) * healthy individuals (fasting serum glucose \< 7 mmol/l) exclusion criteria: * subjects with renal * subjects with hepatic disease * pregnant women * subjects under treatment with insulin and any other hormonal therapies * smoking 12 hours before the intervention * antioxidant supplements 12 hours before the intervention * drugs administration: lipid lowering drugs, oral hypoglycemic agents such as metformin or sulfonylureas 12 hours before the intervention.

Keywords: patients with type 2 diabetes fresh pomegranate juice fasting serum glucose
the impact of hormone therapy on lower urinary tract symptoms, sexual function and psychosomatic disorder

Conditions: Menopausal Syndromes

Summary: menopausal syndromes includes somatic symptom, psychosomatic symptoms, sexual dysfunction and even urinary symptoms. hormone therapy (ht) is widely used for controlling menopausal symptoms. common ht for menopausal syndrome with intact uterus includes tibolone, estradiol valerate (e2v) 1mg \& medroxyprogesterone acetate (mpa) 2.5 mg, and conjugated equine estrogens \& mpa. however, only a few literatures mentioned about the therapeutic effect of tibolone, but lack of comparison research about their therapeutic effect on somatic symptoms, psychosomatic symptoms, sexual dysfunction and even urinary symptoms. the knowledge of the above therapeutic effects should be important for choosing a suitable medication. therefore, the aim of this study is to assess the therapeutic effect on somatic symptoms, psychosomatic symptoms, sexual dysfunction and even urinary symptoms between tibolone and e2v/mpa.


Eligibility criteria:
inclusion criteria: * all female patients with intact uterus who seek for medical treatment for menopausal syndrome exclusion criteria: * patients with gynecologic or breast cancers

Keywords: menopause tibolone estradiol hormone therapy
effects of cimt with and without mit on upper limb of children with hemiparetic cp

Conditions: Cerebral Palsy

Summary: cerebral palsy (cp) is a major cause of motor disability in children. among these cp children, approximately one third have hemiparetic cerebral palsy. hemiparetic cerebral palsy is more impairment of one side of the body as a result of non-progressive disturbances in premature brain.to determine the effects of implementing a practice period of modified constraint induced movement therapy in a virtual environment on hand function in chidren with hemiparetic cerebral palsy.

to determine the effects of implementing a practice period of modified constraint induced movement therapy in a virtual environment on hand function in chidren with hemiparetic cerebral palsy.the term modified constraint-induced movement therapy is a form of rehabilitation therapy that limits the less paretic side, and through repeated and concentrated training improve the upper limb function of the paretic side. motor imagery is a cognitive process in which a subject imagines that he or she performs a movement without actually performing the movement and without even tensing the muscles. modified constraint induced movement therapy can be utilized in both the lower and upper extremities with the motor imagery technique for psychological or occupational therapy and in affecting which one is better for speedy recovery.

Eligibility criteria:
inclusion criteria: * age 6 to 14 years were included. * diagnosed of hemiparetic cerebral palsy and typically developing controls. * both gender is included i-e, male and female. * children included having motor impairments of upper limb. * all children had normal or corrected vision and the ability to discriminate between right and left. exclusion criteria: * history of neurosensory and neuropsychiatric impairments. * presence of contractures in the affected upper limb. * surgery in the previous six months. * uncontrolled epilepsy

Keywords: mcimt, motor imagery technique, hemiparetic cp, rct
hepatitis b antigen kidney graft into protective level hepatitis b antibody recipients

Conditions: HBsAg(+) Donor Kidney Allograft; HBsAg(-) Donor Kidney Allograft

Summary: to determine the safety of using kidney organ from hepatitis b surface antigen positive donor, the author conducted the single-center, prospective study of the use of these kidneys for recipients who have protective level of hepatitis b surface antibodies.

the kidney transplant registry was conducted in kcmh since the year of 2000 until the present. the inclusion criterion was: * all kidney allograft recipients who received at least one month after transplantation. * all kidney recipients who already had the protective antibody against hepatitis b virus infection defined by anti-hbs titer above 100 miu/ml at pre-transplantation period. the exclusion criterion was: * the recipients with positive hepatitis c virus antibody. * the recipients who had received a previous or simultaneous non-kidney solid organ transplant. * the recipients those lost to follow-up. study group: * the recipients who received kidney allograft from the hbsag(+) donor. control group: * the recipients who received kidney allograft from the hbsag(-) donor. according to the thai red cross national organ donation and our institute's policy, the hbsag(+) kidney allografts were distributed to only and informed consent. data collection: * baseline characteristic data e.g. donor and recipient age, donor and recipient gender, hla, pra, anti-hbs titer, immunity against hbv status (both natural and vaccinated),immunosuppressive regimens were collected. * the recipients were prospective followed up at month 3, 6, 9, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120. * clinical data including jaundice, hepatitis, graft rejection were collected * laboratory data of hbsag, anti-hbc, hbv dna, sgot, sgot, egfr were collected. * pathological data of allograft biopsy at month 12 and 24 were retrieved. outcomes: * primary outcome: hepatitis b transmission rate. * secondary outcome: graft survival, patient survival.

Eligibility criteria:
the inclusion criterion was: * all kidney allograft recipients who received at least one month after transplantation. * all kidney recipients who already had the protective antibody against hepatitis b virus infection defined by anti-hbs titer above 100 miu/ml at pre-transplantation period. the exclusion criterion was: * the recipients with positive hepatitis c virus antibody. * the recipients who had received a previous or simultaneous non-kidney solid organ transplant. * the recipients those lost to follow-up.

Keywords: hbsag(+) donor hbsag(-) donor anti-hepatitis b antibody kidney allograft
efficacy and long-term safety of vildagliptin as add-on therapy to metformin in patients with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: this is a 2-3 period parallel group study with an adaptive element in type 2 diabetes patients receiving vildagliptin as add-on therapy to metformin


Eligibility criteria:
inclusion criteria: * patients 18-78 years old inclusive at visit 1 * t2dm patients treated with metformin for at least 3 months and a stable dose of at least 1500 mg daily for a minimum of 4 weeks prior to visit 1 * patient agreement to maintain same dose of metformin throughout study * hba1c of ≥ 7.0 and ≤ 9.5 % at visit 1 * body mass index (bmi) in the range of 22-45 kg/m2 at visit 1 exclusion criteria: * pregnant or nursing (lactating) women * fpg ≥ 270 mg/dl ( ≥ 15.0 mmol/l)

Keywords: type 2 diabetes vildagliptin
the platelet-rich plasma in the therapy of temporomandibular disorders

Conditions: PRP; Temporomandibular Disorder; Myalgia; Bruxism

Summary: the platelet-rich plasma intramuscular injections into the masseter and temporalis muscle were performed to reduce painful temporomandibular disorder symptoms,such as myalgia, myofascial pain and myofascial pain with referrals. patients(n=120) were randomly divided into two groups: experimental(n=60) and control group(n=60). in controls injections with 0,9% nacl were performed. pain intensity was measured with nprs (numeriic pain rating scale, 0= no pain, 11= the worst pain that one can imagine) before(0 day), during(10 day) and after(20 day) the therapy with prp injections.

patients(n=120) attending the department of temporomandibular disorders and orthodontics at the silesian medical university poland, zabrze were enrolled to the study and randomly divided into one of two groups: experimental and control group. platelet-rich plasma(prp) was prepared for each patient and an intramuscular injections of 0,5 ml prp into 6 points at each side were performed in experimental group. a follow-up appointment was made after 10 and 20 days and in each visit an injection of prp or 0,9% nacl was performed. pain intensity was measured in nprs(numeric pain rating scale) and collected data data were analyzed.

Eligibility criteria:
inclusion criteria: 1. presence of local myalgia, myofascial pain and myofascial pain with referral within masseter muscles according to the diagnostic criteria for temporomandibular disorders (dc/tmd) (ii.1.a. 1, 2 and 3) 2. patient's agreement for taking part into the research study exclusion criteria: 1. patients being treated with or addicted to analgesic drugs and/or drugs that affect muscle function 2. presence of contraindications for injection therapy 3. patients being treated by neurologist for neurological disorders and/or neuropathic pain and/or headache 4. patients after traumas to the head and neck region in the previous 2 years 5. edentulous patients 6. patients after radiotherapy 7. presence of severe mental disorders 8. pregnancy or lactation 9. pain of dental origin 10. presence of malignancy 11. drug and/or alcohol addiction 12. patients with needle phobia
prospective evaluation of open-angle glaucoma subjects on two topical hypotensive medication treated with two istents

Conditions: Subjects With Primary Open-angle Glaucoma (POAG)

Summary: the purpose of this study is to assess efficacy and safety of two istents for the reduction of intraocular pressure associated with primary open-angle glaucoma.

this study evaluates the safety and efficacy of two istents implanted in primary open-angle glaucoma subjects.

Eligibility criteria:
inclusion criteria: * diagnosed with primary open-angle glaucoma (poag) * subjects on two topical hypotensive medications exclusion criteria: * traumatic, uveitic, neovascular, or angle closure glaucoma * fellow eye already enrolled

Keywords: open angle glaucoma surgery glaucoma open-angle ocular hypertension eye diseases
clinical efficacy of abx203 therapeutic vaccine in hbeag negative patients with chronic hepatitis b

Conditions: Chronic Hepatitis B

Summary: the study is an open-label, randomized, comparative, multicenter clinical trial. the purpose of this study is to assess the efficacy of abx203, a new chronic hepatitis b therapeutic vaccine administered as an adjunct therapy to nucleos(t)ide analogs (nucs), in maintaining control of hepatitis b disease after cessation of treatment with nucs in subjects with hbeag negative chronic hepatitis b.


Eligibility criteria:
inclusion criteria: * male or female subject between 18 and 65 years of age at the time of randomization. * must be hbeag negative and anti-hbe abs positive for at least 1 year prior to screening and at screening. * has hbv dna \< 40 iu/ml for at least 1 year prior to screening and at screening * has both alt and ast levels ≤ uln for at least 1 year prior to screening and at screening. * must be hbsag positive at screening. * has been treated with nucs for at least 2 years prior to screening. * has not been treated with peg-ifn or ifn for at least 1 year prior to screening. * for all females, must have a negative serum pregnancy test at screening. for female of childbearing potential, must have been using adequate contraception and must agree to continue to use it during all study period and for 6 months after completion of the study product administration. * has provided written informed consent. exclusion criteria: * has elevated blood levels of alpha-fetoprotein (afp) (\> 500 ng/ml). * has cirrhosis, defined as * platelet count \ 12, or * liver stiffness of 11 kilopascal \[kpa\] as measured by elastography using fibroscan® or .an ast to platelet ratio index (apri) \> 2). * has hepatocellular carcinoma (hcc) (diagnosed by ultrasonography). * has liver decompensation (albumin \< 3.5 g/dl and bilirubin ≥1.3 mg/dl). * is hepatitis c virus (hcv) ab positive at screening. * is hepatitis delta virus (hdv) ab positive at screening. * is human immunodeficiency virus (hiv) ab positive at screening. * has an immune suppressive disorder or treatment with immunosuppressive drugs. * has been treated with corticosteroids within 12 weeks prior to the first administration of study product, with the exception of topical or inhaled corticosteroids. * has been treated with rituximab. * has other hepatic diseases of different etiology (such as auto-immune hepatitis, toxic hepatitis, wilson disease, alcoholic or hemochromatosis). * has a history of allergic disease or reactions likely to be exacerbated by any component of the study products. * has a history of a substance abuse (drug or alcohol) problem within the previous 3 years.